The regenerative biostimulator that renews skin from within1-6

Elevate body confidence

Aesthetic goals are evolving7-10, with people moving beyond facial rejuvenation and age-related concerns toward solutions that elevate body confidence at every stage of life.11-14

 

Foundational strength

Sculptra® goes beyond simply addressing wrinkles — it strengthens the skin’s foundation for a healthier looking appearance.15-21

 

Tailored treatment

Treatment can be tailored to your goals, whether you wish to improve skin quality, firmness, volume, contour, or a subtle lifting effect.15,22-31

 

Enhance, shape and contour

As the first proven regenerative biostimulator, Sculptra® re-engages your skin’s natural renewal process, stimulating collagen and elastin to progressively enhance firmness, shape, and contour for a naturally sculpted look.1,6,15-16,19,24-31,33-34,36,38-41

 

What are regenerative biostimulators?

Sculptra® is a unique regenerative biostimulator that is made with the plant-based PLLA-SCA™ formulation, 1,3,8-39,41-42 which works across all 3 skin layers of the skin to renew healthy tissue.36,43-45

Sculptra® targets key components of the skin required to combat signs of aging, including stimulating your own collagen and elastin, with a positive impact on healthy fat. 36,40,43-44,46-48

Discover what Sculptra® can do for you

From face to body, Sculptra® helps improve skin firmness, smoothness and radiance — enhancing natural-looking shape and supporting long-lasting confidence.1,15-16,21,34-35,49-53

Explore Sculptra® for your face

Restore natural-looking firmness, smoothness and volume while improving radiance and skin quality — for results that last for more than 2 years.1,6,15,19,33-34,54

Explore Sculptra® for your body

Firm, smooth and contour areas such as the arms, thighs and buttocks and decolletage – with patients seeing improvements as early as one month after treatment, with continued improvement observed at 2 months and 1 year*

*Cellulite in the posterior thighs1,27,30-31, 55-62

How long do Sculptra® treatments last?

Look and feel better with skin that feels like you again—for a long time. People are still satisfied with their facial results more than 2 years after treatment.15,33-34

For the body, improvements in firmness, smoothness and cellulite appearance are still visible one year after treatment.30

  • 66.5%

    Increase in type I collagen at 3 months – the most important collagen in relation to skin aging40

  • 89%

    Patients who were still satisfied 2 years after treatment15

  • 97%

    Patients who saw firmer skin on the body one year after treatment30

Before

Patients Recommend

High patient satisfaction 2 years after treatment:15,54

Patients LOOK better

89% said results looked natural15
89% think they look younger15

Patients FEEL better

92% feel better about themselves15
92% feel more confident15

After

We are all Sculptra®

Discover real stories from real patients who embarked on a personal journey with Sculptra® over one year.

My Sculptra® Story

Follow patients’ Sculptra® Stories and hear what they and their healthcare practitioners have to say about Sculptra®.

 

Achieve the look you envision by speaking to a healthcare practitioner today.

 

This material refers to the product certified under Regulation (EU) 2017/745 (MDR). Legacy versions of the product remain available. For full product information and the Instructions for Use (IFU), visit: www.galderma.com/library.

Always consult your healthcare professional for individualized treatment recommendations and to discuss important safety information and risks associated with the use of the products.

References

  1. Sculptra MDR EU IFU
  2. Galderma Receives FDA Approval for New SCULPTRA® Label. Galderma 2021.
  3. Asius J et al. US patent US 7,731,758 B22(010):2010.
  4. Sanofi S.r.l. DEKRA EN ISO 13485:2016 Certificate. Effective Feb 2023
  5. Zhang Y et al. Regen Biomater. 2021;8(5):rbab042.
  6. Widgerow A et al. Comparative gene-signature study of PLLA-SCA vs CaHA. Poster, IMCAS 2024
  7. Cohen JL, et al. J Cosmet Dermatol. 2023;22(11):2889-2901.
  8. Facial Plastic Surgery (2023) As Americans return to the office, AAFPRS unveils aesthetics trends from annual facial plastic surgery survey [Online]. Available at: https://www.aafprs.org/Media/Press_Releases/New-Trends-in-Facial-Plastic-Sur- gery.aspx [Accessed: October 2025].
  9. WGSN (2019) Gen Z: Building New Beauty [Online]. Available at: https://www.wgsn.com/assets/marketing/emails/2019/beauty/ launch/Beauty_Whitepaper_Digital.pdf [Accessed: October 2025].
  10. Liew S, et al. Aesth Plast Surg 2016;40(2):193–201.
  11. Triana L, et al. Aesthetic Plast Surg. 2024;48(20):4217-4227.
  12. El Hawa M, et al. J Cosmet Dermatol. 2025;24(1):e16624.
  13. Fares C, et al. J Cosmet Dermatol. 2025;24(2):e16671.
  14. Fabi S. Fillers for the Décolletage Area. https://assets.bmctoday.net/practicaldermatology/pdfs/PD0915_CF_Fillers.pdf [Accessed: October 2025]
  15. Fabi S, et al. Poster presented at IMCAS World Congress. 26 -28 January 2023. Paris, France.
  16. Bohnert K, et al. Plast Reconstr Surg. 2019;45(5):718–24.
  17. Vleggaar D, et al. J Drugs Dermatol. 2008;7(3):209 -20.
  18.  Li Y, et al. Front Physiol. 2024;15:1346612.
  19.  Mest DR, Humble G. Dermatol. Surg. 2006;32(11):1336–45.
  20. Galderma. Data on file (MA-48830).
  21. Hexsel D, et al. Dermatol Surg. 2020;46(8):1122–4.
  22. Haddad, A et al. Poster presented at IMCAS World Congress. 01-03 February 2024.  Paris, France.
  23.  Bohnert K, et al. Plast Reconstr Surg. 2019;127(4):1684–1692.
  24.  Fabi S, et al. Dermatol Surg. 2024;50(12):1137-1142.
  25.  Valantin MA, et al. AIDS. 2003;17(17):2471–7.
  26.  Sarubi J,et al. J Clin Aesthet Dermatol. 2023;16(6):30-36.
  27.  Mazzuco R, Sadick NS. Dermatol Surg. 2016;42(3):441-443.
  28. Munia C, et al. J Clin Aesthet Dermatol. 2022;15(7):38-42.
  29.  Nikolis A, et al. Dermatol Surg. 2025;51(7):702-709.
  30. Beleznay K, et al. Poster presented at IMCAS World Congress. 01-03 February 2024. Paris, France.
  31.  Haddad A, et al. Aesthetic Plast Surg. 2025;49(5):1507-1517.
  32.  Nikolis A, et al. J Drugs Dermatol. 2022;21(3):295-304.
  33. Brandt FS, et al. Aesthet Surg J. 2011;31(5):521–528.
  34. Narins RS, et al. J Am Acad Dermatol. 2010;62(3):448–462.
  35. Widgerow A, et al. A randomized, comparative study describing the gene signatures of PLLA-SCA™ and CaHA in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; 01–03 Feb 2024; Paris, France.
  36. Huth S, et al. J Drugs Dermatol. 2024;23(4):285–288.
  37. FDA. Summary of safety and effectiveness data. Available at: https://www.fda.gov/medicaldevices/recently-approved-devices/sculptra-p030050s039 [Accessed: August 2025].
  38. Data on file (MA-54151).
  39.  Data on file (MA-46589).
  40. Goldberg D, et al. Dermatol Surg. 2013;39(6):915–922.
  41. FDA. Summary of safety and effectiveness data. Available https://www.accessdata.fda.gov/cdrh_docs/pdf3/p030050s002b.pdf
  42. Morgan P, et al. Poster presented at IMCAS World Congress, 26–28 January 2023, Paris, France.
  43. Waibel J, et al. Poster presented at IMCAS World Congress. 01-03 February 2024. Paris, France.
  44.  Zubair R, et al. Dermatol Surg. 2024;50(12):1155-1162.
  45. Oh S, et al. Antioxidants (Basel). 2023;12(6):1204.
  46. Pfisterer K, et al. Front Cell Dev Biol. 2021;9:682414.
  47. Kim HW, et al. Ann Dermatol. 2023;35(6):424–31.
  48. Trevor LV, et al. J Clin Med. 2020;9(7):2161.
  49. Aziz J et al. Skin Pharmacol Physiol. 2016;29(4):190–203.
  50. Swift A et al. Aesthet Surg J. 2021;41(10):1107–19.
  51. Vierkötter A, Krutmann J. Dermatoendocrinol. 2012;4(3):227–31.
  52. Zhang S, Duan E. Cell Transplant. 2018;27(5):729–38.
  53. Filho C DSM et al. Surg Cosmet Dermatol. 2013;5(4):345–50.
  54. Data on file (MA-48331).
  55. Data on file (MA-54104)
  56. Joseph J, et al. Poster presented at AMWC. 27-29 March 2024. Monte Carlo, Monaco
  57. Galderma. Data on file (MA-57540).
  58. Vanaman M, Fabi S. Plast Reconstr Surg. 2015;136(5 Suppl):276S-281S.
  59. Wilkerson E, Goldberg D. J Cosmet Dermatol. 2017;17(4):606-610.
  60.  Coimbra D, et al. Surg Cosmet Dermatol 2012;4(2):182-5.
  61. Mazzuco R, et al. J Cosmet Dermatol. 2022;21(12):6727-6733.
  62. Lin M, et al. Dermatol Surg. 2020;46(3):386-394.

Job code: UKI-SCU-2600004 Date of Preparation: March 2026

AE Statement: Adverse events should be reported.

For the UK, Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Website: www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd, Email: medinfo.uk@galderma.com, Tel: +44 (0) 300 3035674

Other Disclaimers: ‘Individual results may vary’